Evidence map›Paper›PMID 28359319›Full record

ArticleBreast cancer research : BCR2017

Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65.

Suzanne C O'Neill, Claudine Isaacs, Filipa Lynce, Deena Mary Atieh Graham, Calvin Chao, Vanessa B Sheppard, Yingjun Zhou, Chunfu Liu, Nandini Selvam, Marc D Schwartz and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Suzanne C O'NeillGeorgetown Lombardi Comprehensive Cancer Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC, 20007, USA. sco4@georgetown.edu.
Claudine IsaacsGeorgetown Lombardi Comprehensive Cancer Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC, 20007, USA.
Filipa LynceGeorgetown Lombardi Comprehensive Cancer Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC, 20007, USA.
Deena Mary Atieh GrahamHackensack Meridian Health, Hackensack, NJ, USA.
Calvin ChaoGenomic Health, Inc, Redwood City, CA, USA.
Vanessa B SheppardSchool of Medicine Virginia Commonwealth University, Richmond, VA, USA.
Yingjun ZhouGeorgetown Lombardi Comprehensive Cancer Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC, 20007, USA.
Chunfu LiuHealthCore, Inc, Wilmington, DE, USA.
Nandini SelvamIMS Health, Fairfax, VA, USA.
Marc D SchwartzGeorgetown Lombardi Comprehensive Cancer Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC, 20007, USA.
Arnold L PotoskyGeorgetown Lombardi Comprehensive Cancer Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC, 20007, USA.

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
Impact of Genomic and Personalized Medicine in Women under 65 with Breast Cancer - SupplementR01CA160671 · NCI · GEORGETOWN UNIVERSITY · PI POTOSKY, ARNOLD L · 2012 to 2016
$1.0M
NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA160671
6 · The paper itself

Abstract

backgroundAside from chemotherapy utilization, limited data are available on the relationship between gene expression profiling (GEP) testing and breast cancer care. We assessed the relationship between GEP testing and additional variables and the outcomes of endocrine therapy initiation, discontinuation and adherence, and breast imaging exams in women under age 65 years.

methodsData from five state cancer registries were linked with claims data and GEP results. We assessed variables associated with survivorship care outcomes in an incident cohort of 5014 commercially insured women under age 65 years, newly diagnosed with stage I or II hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2) non-positive breast cancer from 2006 to 2010.

resultsAmong tested women, those with high Oncotype DX® Breast Recurrence Score® (RS) were significantly less likely to initiate endocrine therapy than women with low RS tumors (OR 0.40 (95% CI 0.20 to 0.81); P = 0.01). Among all test-eligible women, receipt of Oncotype DX testing was associated with a greater likelihood of endocrine therapy initiation (OR 2.48 (95% CI 2.03 to 3.04); P <0.0001). The odds of initiation were also significantly higher for tested vs. untested women among women who did not initiate chemotherapy within six months of diagnosis (OR 3.25 (95% CI 2.53 to 4.16)), with no effect in women who received chemotherapy. Discontinuation and adherence and breast imaging exams were unrelated to tested status or RS.

conclusionsLower endocrine therapy initiation rates among women with high RS tumors and among untested women not receiving chemotherapy are concerning, given its established efficacy. Additional research is needed to suggest mechanisms to close this gap.

Indexed as

Gene Expression ProfilingAdultAgedAged, 80 and overAge FactorsBreast NeoplasmsChemotherapy, AdjuvantFemaleHumansKaplan-Meier EstimateMedication AdherenceMiddle AgedNeoplasm StagingOdds RatioRecurrenceRisk FactorsBreast cancerBreast imagingEndocrine therapyGene expression profilingGenomic testing

Identifiers

PMID28359319
PMCPMC5374604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.